Preclinical studies of a PARP-targeted theranostic radiopharmaceutical for pancreatic cancer
The PEG-modified PARPi probe not only retained high affinity and targeting capability but also significantly improved retention time during <i>in vivo</i> trials.
Authors
- Jianguo Li (ORCID: https://orcid.org/0000-0003-0520-7302)
- Jie Gao (ORCID: https://orcid.org/0000-0003-1317-2445)
- Yuhao Wang (ORCID: https://orcid.org/0000-0003-3557-3557)
- Hongliang Wang (ORCID: https://orcid.org/0000-0002-4389-2761)
- Mengya Liu (ORCID: https://orcid.org/0000-0002-8875-6907)
- Ruoqi Wang (ORCID: https://orcid.org/0009-0005-6989-1926)
Institutions
- Shanxi Medical University (CN)
- China Institute of Atomic Energy (CN)
- National Radio Research Agency (KR)
- First Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fphar.2025.1576587
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Shanxi Province